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Robert C. Spencer, David M. Devilbiss, and Craig W. Berridge*
Department of Psychology, University of Wisconsin, Madison, WI

Abstract
Author Manuscript
Author Manuscript

Psychostimulants are highly effective in the treatment of attention deficit hyperactivity disorder
(ADHD). The clinical efficacy of these drugs is strongly linked to their ability to improve
cognition dependent on the prefrontal cortex (PFC) and extended frontostriatal circuit. The
procognitive actions of psychostimulants are only associated with low doses. Surprisingly, despite
nearly 80 years of clinical use, the neurobiology of the procognitive actions of psychostimulants
has only recently been systematically investigated. Findings from this research unambiguously
demonstrate that the cognition-enhancing effects of psychostimulants involve the preferential
elevation of catecholamines in the PFC and the subsequent activation of norepinephrine α2- and
dopamine D1 receptors. In contrast, while the striatum is a critical participant in ‘PFC-dependent’
cognition, where examined, psychostimulant action within the striatum is not sufficient to enhance
cognition. At doses that moderately exceed the clinical range, psychostimulants appear to improve
PFC-dependent attentional processes at the expense of other PFC-dependent processes (e.g.
working memory, response inhibition). This differential modulation of PFC-dependent processes
across dose appears to be associated with the differential involvement of noradrenergic α2 vs. α1
receptors. Collectively, this evidence indicates that at low, clinically-relevant doses,
psychostimulants are devoid of the behavioral and neurochemical actions that define this class of
drugs and instead act largely as cognitive enhancers (improving PFC-dependent function). This
information has potentially important clinical implications as well as relevance for public health
policy regarding the widespread clinical use of psychostimulants and for the development of novel
pharmacological treatments for ADHD and other conditions associated with PFC dysregulation.
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Psychostimulants elicit potent arousing, behaviorally-activating and reinforcing actions that
are associated with significant potential for abuse (1–6). Nonetheless, these drugs are highly
effective in treating hyperactivity, impulsivity and inattention associated with attention
deficit hyperactivity disorder (ADHD; 7–10). Given these apparently contradictory actions,
it was initially proposed that psychostimulants acted ‘paradoxically’ in individuals with
ADHD: calming, rather than activating behavior. This ‘paradoxical hypothesis’ strongly
influenced clinical and basic science research into the neurobiology and pharmacology of
ADHD.

Author Manuscript

A major breakthrough in our understanding of psychostimulant action was the
demonstration in 1980 that the cognition-enhancing and behavioral-calming actions of
psychostimulants are not unique to ADHD, with similar effects seen in healthy human
subjects (11). This and subsequent studies unambiguously demonstrate that when used at
low and clinically-relevant doses, psychostimulants improve prefrontal cortex (PFC)dependent behavioral/cognitive processes in human subjects with and without ADHD (11–
15). This ability of psychostimulants to act as cognitive enhancers drives the recent growth
in use of these drugs by the general population to improve academic and work-related
performance (16–18). Low-dose psychostimulant improvement in PFC-dependent function
is consistent with evidence indicating ADHD involves dysregulation of the PFC and
extended frontostriatal circuitry (19–22). Moreover, the procognitive actions of
psychostimulants are also observed in ‘normal’ animal subjects (see Figure 1; 5,6,23,24),
indicating an animal model of ADHD is not required to study the neural mechanisms
underlying the cognition-enhancing/therapeutic effects of psychostimulants. This is an
important advantage given there are no animal models known to definitively mimic the
neurobiology of ADHD.

Author Manuscript

Collectively these observations indicate that the neural mechanisms responsible for the
therapeutic/cognition-enhancing effects of low-dose psychostimulants cannot be
extrapolated from actions of higher doses that exert opposing behavioral and cognitive
effects. Over the past 10 years, correlative evidence has suggested the hypothesis that the
PFC is a key site in the cognition-enhancing actions of psychostimulants (for review, 25,26).
More recent work provides critical, causal evidence for a role of the PFC in the cognitionenhancing effects of psychostimulants. In the following sections we review the collective
body of research on the neurobiology of clinically-relevant and procognitive doses of
psychostimulants.

Clinically-Relevant Doses of Psychostimulants Elevate Catecholamine
Author Manuscript

Signaling Preferentially in the PFC
The two most commonly used psychostimulants in the treatment of ADHD are
methylphenidate (MPH; e.g. Ritalin®) and amphetamine (e.g. Adderall®). At behaviorallyactivating doses, these drugs potently increase extracellular levels of norepinephrine (NE)
and dopamine (DA) throughout the brain, largely by blocking NE and DA reuptake (27,28).
Some psychostimulants, particularly amphetamine, actively stimulate DA efflux through the
DA transporter (29). Although amphetamine can also stimulate NE efflux and block
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serotonin reuptake, these actions only occur at high and clinically-inappropriate doses (30).
In contrast, MPH acts only to block NE and DA reuptake, neither inhibiting serotonin
reuptake nor stimulating NE or DA efflux (31).

Author Manuscript

Early animal studies demonstrated a central role of DA acting in the striatal subregion, the
nucleus accumbens (NAcc), in the motor activating and reinforcing effects of higher doses
of psychostimulants. Based on this, the early clinical literature emphasized the potential role
of NAcc DA in the therapeutic effects of psychostimulants. However, given low, clinicallyrelevant doses of psychostimulants exert qualitatively different behavioral effects vs. higher,
behaviorally-activating doses, the neurobiology of higher doses may not have strong
translational relevance. However, in order to study the clinically-relevant actions of
psychostimulants in animals, it is essential to identify doses that model clinical use.
Pharmacokinetic studies identified doses of MPH in animals that elicit plasma
concentrations associated with clinical efficacy in humans (~10–40 ng/ml; 23,24,32,33). In
rats, clinically-relevant plasma levels are seen following 1.0–3.0 mg/kg MPH given orally
and 0.25–1.0 mg/kg MPH administered intraperitoneally (24,32,33). At these doses, MPH is
largely devoid of behaviorally-activating or arousing actions (Figure 1; 24,32,33).
Moreover, under conditions associated with elevated locomotor activity, these clinicallyrelevant doses of MPH suppress motor activity, similar to that seen in ADHD (Figure 1; 33).
Finally, these doses of MPH improve PFC-dependent cognition (working memory, sustained
attention), similar to that seen in humans (Figure 1; 5,24,34). The behavioral/cognitive
effects of low and clinically-relevant doses contrast with the motor activating, arousalpromoting, and cognition-impairing actions associated with abuse-related doses of
psychostimulants.

Author Manuscript

Microdialysis studies demonstrate that clinically relevant doses of MPH elicit prominent
increases in extracellular NE and DA within the PFC (100–250%; Figure 2). In contrast,
substantially smaller effects are observed on DA levels in the NAcc and NE levels in the
medial septum, regions associated with psychostimulant-induced motor activation and
arousal, respectively (see Figure 2; 24,32,33,35–39). As with the cognitive effects of MPH
(6,24), the preferential targeting of PFC catecholamines is not dependent on route of
administration, as long as dose is adjusted to yield similar plasma concentrations (24). These
doses of MPH increase hippocampal and somatosensory cortical NE levels similar to that
seen in the medial septal area (32,33,40), indicating the greater sensitivity of PFC
catecholamines reflects a relatively unique aspect of PFC physiology (32,33,40).

Author Manuscript

The modest actions of low-dose psychostimulants on extracellular catecholamines in
subcortical regions associated with motor activation (e.g. accumbens) and arousal (e.g.
medial septum) appears to explain why, clinically, psychostimulants are devoid of the
prototypical behavioral-activating and arousal-enhancing effects of psychostimulants.
Moreover, the fact that low-dose psychostimulants do not increase, and may reduce, drug
abuse in ADHD patients (41,42) is consistent with a relatively modest impact of clinicallyrelevant doses on neural circuitry posited to underlie drug abuse (e.g. NAcc DA; 39).
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Potential Mechanisms Underlying the Preferential Sensitivity of PFC
Catecholamines
The above-described studies fail to identify the circuit mechanisms associated with the
preferential sensitivity of PFC catecholamines. Recent studies using reverse microdialysis
demonstrate that when infused in low concentrations, MPH elicits significantly larger
increases in extracellular NE and DA in the PFC relative to the medial septum or NAcc
(Figure 3; 43). This selectivity for the PFC disappeared with higher concentrations of MPH,
similar to that seen with systemic administration (24,31). These observations demonstrate
that the enhanced sensitivity of PFC catecholamines reflects, at least in part, an intrinsic
property of the PFC.

Author Manuscript
Author Manuscript

The mechanisms within the PFC responsible for the increased sensitivity of PFC
catecholamines are less clear. However, this may involve the fact that the density of DA
transporters (DAT) is sparse in the PFC relative to the striatum (44,45), largely consistent
with the reduced density of DA innervation of the PFC relative to the striatum (except see,
45). Moreover, the NE transporter (NET) displays a high affinity for DA and plays a
prominent role in PFC DA clearance (46–48). Consistent with this, selective NET inhibitors
effective in ADHD increase both NE and DA in the PFC without altering striatal DA
(Figure 4; 49,50). It is important to note that ‘limited’ DAT density in the PFC (relative to
the striatum) does not indicate an absence of functional DAT. Indeed, evidence
demonstrates measurable DAT in the medial PFC of rats (44,45). Further, DAT inhibitors
are known to elevate extracellular DA levels in this region (43,51,52). Moreover, recent
studies demonstrate that when administered at a cognition-enhancing dose, a selective DAT
inhibitor increases both extracellular DA and NE in the PFC similar to cognition-enhancing
doses of psychostimulants (Figure 4; 53). The elevation in NE is posited to result indirectly
from drug-induced increases in extracellular DA that compete with NE at the NET, resulting
in an increase in extracellular NE.

Author Manuscript

Collectively, these observations suggest that, in the PFC, NE and DA competitively bind to
the NET, with elevations in one transmitter increasing extracellular levels of the other. We
posit that this ‘feed-forward’ mechanism contributes to the preferential sensitivity of PFC
catecholamines to clinically-relevant doses of psychostimulants. These observations further
indicate a close relationship between drug-induced increases in PFC catecholamines and the
cognition-enhancing effects of a variety of drug classes, including psychostimulants, NET
inhibitors and DAT inhibitors. Specifically, at cognition-enhancing doses all of these drugs
elicit moderate elevations in PFC NE and DA of ~100%–250%. In contrast, the effects of
these drugs on striatal DA fail to predict their cognition-enhancing effects (a range of 0%–
200%; see Figures 2 and 4).

Do the Cognition-Enhancing Effects of Psychostimulants Involve Direct
Action Within the PFC?
Though correlative in nature, the neurochemical effects of low-dose psychostimulants
reviewed above suggest the hypothesis that the PFC is an important site of action in the
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cognition-enhancing properties of these drugs. As in primates, the rat medial PFC is
functionally and anatomically heterogeneous, with the dorsomedial PFC (dmPFC; i.e. dorsal
anterior cingulate, dorsal prelimbic PFC) associated with flexible cognitive function and the
ventromedial PFC (vmPFC; i.e. infralimbic PFC, ventral prelimbic PFC) associated with
affective/motivationrelated processes (54–57). Recent studies demonstrate that when infused
directly into the rat dmPFC, but not vmPFC, MPH facilitates working memory in an
inverted-U shaped manner, comparable to systemic administration (Figure 5; 58). Thus,
MPH action in the dmPFC is sufficient to elicit cognitive improvement.

Author Manuscript

In contrast to the cognition-enhancing effects of systemically administered clinicallyrelevant doses of MPH, 4–8-fold higher doses impair working memory (Figure 1). Thus, it is
surprising that intra-PFC MPH fails to impair performance, even at concentrations 16-fold
and 32-fold higher than a performance-improving concentration (Figure 5; 58). These
observations indicate: 1) there is a mechanism within the PFC that drives the descending
limb of the inverted-U curve (to zero) and 2) the cognition-impairing actions of systemically
administered psychostimulants involve drug action outside the PFC. A possible candidate
system for the cognition-impairing effects of psychostimulants is the hypothalamo-pituitaryadrenal (HPA) axis. Thus, behaviorally-activating doses of psychostimulants activate the
HPA axis, elevating circulating glucocorticoids (59) and impair spatial working memory
through glucocorticoid receptor activation within the PFC (60). Clinically, it would likely be
beneficial to extend the effective dose range of psychostimulants, particularly in patients that
do not respond optimally to lower doses. Understanding the neural mechanisms responsible
for the cognition-impairing actions of psychostimulants is a translationally important area
for future research.

Author Manuscript

Psychostimulant Action Outside the PFC: Striatum

Author Manuscript

The above reviewed information unambiguously demonstrates the PFC is a key region for
the cognition-enhancing/therapeutic effects of psychostimulants. Nonetheless, the PFC does
not act in isolation to support higher cognitive function, representing one node in a broader
corticothalamocortical circuit. As part of this, the PFC extends topographically organized
projections to the striatum (61,62), a region that plays a prominent role in cognitive
processes historically associated with the PFC and dysregulation of frontostriatal circuitry is
implicated in ADHD (20). Thus, it is of interest that clinically-relevant doses of MPH
increase striatal DA signaling in both humans and animals (24,63,64), albeit to a lesser
degree than in the PFC (Figure 2; 24). Furthermore, in humans, cognition-enhancing actions
of MPH are associated with changes in DA signaling in both the dorsal and ventral striatum
(63,65). However, an important caveat to these imaging studies is that catecholamine
signaling in the PFC was not measured. Based on the observations reviewed above (Figure
2) it is likely that a similar, if not stronger, relationship exists between drug-induced changes
in cognition and catecholamine signaling in the PFC. Nonetheless, collectively, these
observations suggest that psychostimulant-induced increases in DA in the striatum could
contribute to the cognition-enhancing effects of psychostimulants.
In rats, the dorsomedial and ventromedial striatum receive direct projections from the
dmPFC (57,58,66), a region associated with the cognition-enhancing actions of MPH (see
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above). Inactivation or lesion of either the dorsomedial or ventromedial striatum
significantly impairs working memory (Figure S1; 58,67). Nonetheless, MPH infusion into
either of these striatal regions (Figure S1; 58) has no effect on working memory
performance. Thus, unlike the dmPFC, psychostimulant action within the striatum is not
sufficient for the working memory enhancing effects of MPH. Nonetheless, drug-induced
alterations in PFC neuronal function are likely relayed to downstream targets, altering the
overall function/activity of frontostriatal-thalamocortical networks. Additionally, it remains
possible that although action in the striatum is not sufficient for the procognitive effects of
psychostimulants, combined actions in the PFC and striatum may contribute to the maximal
therapeutic effects of these drugs.

Clinically-Relevant Doses of Psychostimulants Strengthen Neuronal
Author Manuscript

Signaling in the PFC

Author Manuscript

A number of imaging studies indicate that cognition-enhancing doses of psychostimulants
normalize ADHD-related hypoactivity within frontostriatal circuitry (12,68–70). However,
additional evidence indicates that clinically-relevant doses of psychostimulants exert a more
complex pattern of actions on frontostriatal activity that are task, region, and hemispheredependent (13,71–74). Currently, there exists only limited information regarding the
electrophysiological mechanisms that underlie the cognition-enhancing effects of
psychostimulants. In unanesthetized animals, cognition-enhancing doses of MPH increase
the responsiveness of PFC neurons to afferent signals while exerting minimal effects on
spontaneous discharge rates (Figure S2; 6). Similar to that seen neurochemically (see Figure
2), these doses of MPH do not alter neuronal discharge properties of cortical neurons outside
the PFC (e.g. somatosensory cortex; 6,40). A similar improvement in PFC signal processing
is observed with cognition-enhancing doses of the NET inhibitor, atomoxetine (34).

Author Manuscript

Combined, these observations suggest that the procognitive/therapeutic effects of
psychostimulants involve strengthening of signal processing within the PFC. This action
may bias neuronal activation to salient, task-related information while simultaneously
reducing responding to less-salient or irrelevant stimuli. Conversely, the cognition-impairing
effects of higher, motorically activating doses of psychostimulants likely involve
suppression of neuronal signal processing in the PFC. A similar pattern of low and high dose
effects on PFC reactivity has been observed in human imaging studies (75–77). Finally, as
reviewed above, psychostimulant action in the PFC is expected to alter signal processing
broadly within corticostriatal-thalamocortical loops. Further studies will need to explore
how MPH alters signal processing within this broader circuitry involving flexible goaldirected behavior.

Receptor Mechanisms in the PFC: NE α2 and DA D1 receptors
DA and NE exert an inverted-U shaped facilitation of both PFC dependent working memory
and PFC neuronal signaling. In the case of DA, these actions involve inverted-U shaped
modulatory actions of D1 receptors (78). For NE, high-affinity postsynaptic α2 receptors
improve, whereas lower affinity α1 receptors, engaged at higher rates of NE release, impair
working memory and PFC neuronal signaling (79). Importantly, α2-agonists are efficacious
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in the treatment of ADHD and improve PFC-dependent function in healthy animal and
human subjects (80–84), similar to that seen with psychostimulants and selective NE
reuptake blockers used in ADHD. Moreover, similar to MPH, α2-agonist infusion into the
PFC improves working memory performance and PFC neuronal signaling (85).
This evidence suggests that PFC α2 and/or D1 receptors play a prominent role in the
cognition-enhancing actions of low-dose psychostimulants. Consistent with this, the
working memory effects of both low-dose MPH and the selective NET inhibitor,
atomoxetine, are prevented with systemically administered α2 and D1 antagonists (Figure
S3; 5,34). Moreover, we recently observed that the cognition-enhancing effects of intraPFC infusion of MPH are blocked by co-infusion of α2 and D1 antagonists (86).

Author Manuscript
Author Manuscript

The neurophysiological actions of clinically-relevant doses of psychostimulants described
above likely involve catecholamine-dependent modulation of amino acid signaling. Thus,
catecholamines exert receptor-dependent modulation of excitatory and inhibitory amino acid
signaling in a variety of brain regions (87–89), including the PFC (90,91). In the PFC,
NMDA-receptor mediated excitatory postsynaptic currents (EPSCs) are potentiated by a
cognition-enhancing dose of MPH, an action that involves D1 receptors (89–91). Moreover,
at least a subset of catecholamine actions in the PFC is linked to the modulation of
hyperpolarizationactivated cyclic nucleotide (HCN) channels (92). Of particular relevance to
the current discussion, stimulation of cognition-enhancing postsynaptic α2 receptors in the
PFC inhibit HCN channels, enhancing neuronal responsiveness to behaviorally salient
signals (92). Thus, this mechanism may contribute to the psychostimulant-induced
strengthening of PFC neuronal responding. In contrast, suppressive effects of high dose
psychostimulant on evoked discharge of PFC neurons (reduced by ~80%; Figure S2; 6)
involve D1-mediated activation of HCN channels and/or α1-mediated activation of SK
channels (92). Additionally, psychostimulant-driven reductions in evoked discharge may
involve suppression of glutamatergic signaling, as high doses of MPH (8.0 mg/kg) suppress
both NMDA and AMPA-receptor mediated EPSCs (89).
Combined, the available evidence indicates that the procognitive and enhanced neuronal
signal processing actions of psychostimulants (and selective NE-reuptake blockers and α2
agonists) involve moderate increases in NE α2 and/or DA D1 receptor activation in the PFC.
Conversely, the cognition-impairing actions of higher doses of psychostimulants likely
involve suppression of signal processing in the PFC via high rates of α1 and D1 receptor
activation.

Differing Dose-Response Curves Across Cognitive Tasks Reflect Differing
Author Manuscript

Noradrenergic Receptor Action
In 1977 Sprague and Sleator reported that in ADHD children, MPH elicited a narrow
inverted-U shaped facilitation of performance in a ‘cognition/learning’ task, while classroom
behavior was improved across a wider dose range (93). However, subsequent studies
generally failed to observe differential sensitivity to MPH dose across a range of cognitive
tasks vs. overt behavior in ADHD patients (94–96). Importantly, Sprague and Sleator used a
memory task that involved short delays (seconds), typical of PFC-dependent working
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memory tasks, while subsequent studies examined other forms of cognition (93,94). MPH
was also observed to produce a narrow inverted-U shaped improvement in a PFC-dependent
test of response inhibition in ADHD patients while eliciting a generally linear dosedependent improvement in behavioral/motor activity (96).

Author Manuscript

These observations could suggest that psychostimulants exert differential dose-dependent
effects on PFC-dependent vs. PFC-independent processes. However, when the dosedependent actions of MPH were compared across working memory and sustained attention
tasks, two PFC-dependent tasks (Figure S2; 97), a narrower, left-shifted inverted-U curve
was observed for working memory vs. sustained attention (Figure 6; 98). A similar shift in
dose response curves across these tasks occurs with MPH infusion directly into the dmPFC
(99). Prior studies have suggested that PFC NE may differentially regulate flexible vs.
focused attention (100,101). Sustained attention requires little cognitive flexibility, relative
to working memory. However, when examined in a PFC-dependent attentional set shifting
task typically used to measure flexible attention (102,103), MPH elicited dose-dependent
improvements in performance identical to sustained attention (Figure 6; 98). Collectively,
these observations indicate that differing PFC-dependent cognitive processes display
differing dose sensitivity to MPH that are not predicted by the degree to which they are
associated with cognitive flexibility.

Author Manuscript

As reviewed above, noradrenergic α2-receptors improve, while α1-receptors impair,
working memory (104). In contrast, α1-receptors improve attentional set shifting while α2receptors have little impact in this task (100). These observations suggest the hypothesis that
the narrow vs. broad inverted-U shaped actions of psychostimulants described above involve
differential activation of α2- vs. α1-receptors, respectively. Consistent with this, MPHinduced improvement in working memory is dependent on α2 receptors (see above; 104)
while MPH-induced improvement in sustained attention is dependent on α1 receptors (98).

Implications for Divergent Dose-Response Curves Across PFC-Dependent
Processes

Author Manuscript

Preclinically, the differential dose sensitivity of PFC-dependent tasks to psychostimulants
suggests that not all PFC-dependent tasks are well suited for ADHD-focused drug discovery
programs. Extensive evidence demonstrates that the pharmacology of working memory
mirrors the pharmacology of ADHD: all approved ADHD-related drugs, including α2
agonists (105), low-dose psychostimulants (5,25) and selective NE reuptake blockers (e.g.
atomoxetine; 34) improve working memory. For psychostimulants, their beneficial effects
on working memory only occur across a narrow range of doses that produce clinicallyrelevant plasma concentrations (32,33,37,105,106). Thus, delayed response tests of working
memory are a well-suited preclinical tool for identifying potentially efficacious compounds
for use in ADHD and possibly other clinical conditions associated with PFC dysfunction.
In contrast, in sustained attention, attentional set shifting, and 5-choice serial reaction time
tests, MPH exerts maximal beneficial actions at higher, behaviorally-activating and
impulsivity-promoting doses that result in blood concentrations that exceed the clinicallyrelevant range (Figure 1; 33,37,107,108). Moreover, limited observations indicate that α2-
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agonists lack beneficial effects on attentional set shifting (100) as well as sustained attention
(unpublished observations, JL Berkowitz, BD Waterhouse, JS Shumsky). Thus, the potential
utility of these tests in an ADHD-focused preclinical program is less clear.

Author Manuscript

Clinically, as suggested by Sprague and Sleator (93) and Tannock and colleagues (96),
differential actions of psychostimulants across cognitive processes raise the question of
whether doses that are optimal for controlling classroom behavior impair, or no longer
improve, cognitive/behavioral processes important for other functional domains. For
example, largely anecdotal evidence suggests that cognitive-constriction or over-focusing
can be a side effect of psychostimulant treatment (96). This action may be related to the
ability of higher doses of MPH to improve attentional processes while impairing certain
forms of cognitive flexibility evinced in tests of working memory and response inhibition
(96,98,107). If so, the results reviewed above could suggest the use of α1-antagonists as an
adjunct treatment for ADHD. Given α1 receptors in the PFC are necessary for the motoractivating and reinforcing effects of psychostimulants, α1 antagonists may also lessen
certain adverse actions of psychostimulants, including abuse liability. Further studies are
needed to better understand the degree to which the dose-dependent actions of
psychostimulants across PFC-dependent processes relate to clinical, social, and academic
outcomes and role of α1-receptors in these actions.

Summary and Implications

Author Manuscript
Author Manuscript

Low-dose psychostimulants are the first-line treatment for ADHD. At clinically-relevant
doses these drugs improve frontostriatal cognitive function in ADHD patients and healthy
individuals. The procognitive and behavioral calming actions of psychostimulants are in
stark contrast to the behaviorally-activating and cognition-impairing effects seen with higher
doses. For much of the history of psychostimulant treatment of ADHD there has been an
emphasis on the possible involvement of striatal DA signaling in the therapeutic actions of
these drugs. Much of this view was driven by the known neurobiological actions of high and
behaviorally-activating doses. However, research over the past ten years has provided
significant insight into the neural mechanisms that support the procognitive/therapeutic
effects of psychostimulants. In particular, evidence demonstrates that the cognitionenhancing effects of psychostimulants involve an elevation in catecholamine signaling at α2
and D1 receptors preferentially within the PFC. The regionally-selective action of low-dose
psychostimulants contrasts with the widespread and uniform actions of higher doses of these
drugs. This regional selectivity appears to explain why the clinical use of psychostimulants
is not associated with the pronounced arousal, motor activation and abuse liability of higher
doses. Evidence also indicates PFC D1 and/or α2 receptors contribute to the the therapeutic
actions of the two other FDA approved treatments: selective NE reuptake inhibitors and α2
agonists. Collectively, this indicates a prominent role of PFC catecholamines in the
pharmacology of ADHD. In identifying the PFC as a key site of action in the procognitive
effects of psychostimulants, this research provides important guiding information for future
drug discovery research focused on ADHD. It is hoped further understanding of the
neurobiology of the PFC will lead to the identification of novel, non-catecholamine targets
for ADHD and other disorders of frontostriatal function.
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From a public policy perspective, there has been significant concern about the widespread
use of ‘psychostimulants’ in the treatment of ADHD. In the discussion of this issue, the term
‘psychostimulant’ often carries strong negative connotations that are associated with the
arousing, activating and abuse liability of these drugs. However, information reviewed
above demonstrates that at low and clinically relevant doses, psychostimulants do not exert
behavioral and neurochemical actions that define this class of drugs. Instead at these lower
doses, these drugs act as ‘cognitive enhancers’ that improve frontostriatal cognitive function
while exerting only modest effects in neural circuits associated with psychostimulant-related
arousal, motor activation and abuse. While this does not indicate these drugs are devoid of
risk, it is important information for policy-based discussions regarding the appropriateness
of the clinical use of ‘psychostimulants’. One important caveat to this discussion is that the
vast majority of studies on the neural and behavioral actions of clinically relevant doses of
psychostimulants in both humans and animals have largely involved males. Extending this
work to females is an important area for future research.
Finally, it is now clear that psychostimulants do not exert a uniform facilitation of PFCdependent processes. In particular, in both animals and humans, lower doses maximally
improve performance in tests of working memory whereas maximal suppression of overt
behavior and facilitation of attentional processes occurs at higher doses. These differing
sensitivities of PFC-dependent processes appear to depend on differential involvement of α2
vs. α1 receptors. These observations raise a number of clinical and preclinical questions
regarding the degree to which higher doses that maximally control classroom behavior may
exert detrimental actions in other functional domains via activation of α1 receptors.
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Fig 1. Behavioral-calming and cognition-enhancing actions of clinically-relevant doses of
methylphenidate (MPH) in rats

Author Manuscript

A: Lack of locomotor activation. Bars indicate motor counts (quadrant entries + rears) in
the 90-minute period following subcutaneous treatment with vehicle (VEH) or varying doses
of MPH (0.5, 1.0, 2.0 and 4.0 mg/kg) during the light (inactive) phase of the circadian cycle
in rats (i.e. under low arousal conditions). Doses that produce clinically-relevant plasma
concentrations (0.5, 1.0 mg/kg) do not elicit significant locomotor activation. Higher doses
elicit dose-dependent increases in locomotor activity. The 4.0 mg/kg dose was peri-threshold
for eliciting mild stereotypy. B: Motoric calming. When tested under conditions associated
with elevated motor activity (during the dark/active phase) clinically relevant doses of oral
MPH (1.0, 3.0 mg/kg) suppressed motor activity, similar to that seen in ADHD patients. C,
D: Cognition enhancement. When administered in doses that elicit clinically relevant
plasma concentrations, intraperitoneally (C) or orally (D) administered MPH improves
working memory performance as measured by percent change from baseline performance in
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a delayed-response test of working memory (T-maze). 4-fold higher doses impair or do not
improve performance. All bars indicate mean ± SEM. *P<0.05, **P <0.01 compared with
vehicle-treated animals. Modified from (6,24,33).
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Fig 2. Clinically relevant doses of methylphenidate (MPH) preferentially increase extracellular
catecholamines within the prefrontal cortex (PFC)
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A–C: Shown are the mean ± SEM catecholamine levels expressed as a percentage of
baseline (±SEM) values in 16-minute microdialysis samples collected before (negative
numbers) and after (positive numbers) injection of vehicle (VEH) or MPH. Clinicallyrelevant doses of MPH administered orally (A; 2.0 mg/kg) or intraperitoneally (B; 0.5
mg/kg) elicited large increases in extracellular dopamine (DA) within the PFC relative that
that seen in the nucleus accumbens (NAcc). (C) Similarly, for norepinephrine (NE),
intraperitoneal administration of 0.5 mg/kg MPH elicited a large increase in extracellular NE
in the PFC with little change in the medial septal area (MSA). For both DA and NE,
although clinically relevant doses of MPH elicit smaller effects outside the PFC, these
effects are nonetheless statistically significant relative to both baseline and vehicle-treated
animals. D: Bars represent effects of 0.5 mg/kg MPH intraperitoneally expressed as a %
change from vehicle-treated animals (mean ±SEM) for DA and NE over a 30-minute period
beginning at 15-minutes post-treatment. When measured in this manner, although MPH
increases NE and DA outside the PFC by ~30% this effect was not significantly
significant. *P<0.05, **P <0.01 compared with vehicle-treated animals. #P<0.01 relative to
PFC DA. From (24).
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Fig 3. Preferential sensitivity of PFC catecholamines involves local mechanisms
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Locally administered methylphenidate (MPH) increases dopamine (DA) and norepinephrine
(NE) preferentially within the prefrontal cortex (PFC). Shown are the effects of local
application of 1.0 µM MPH on extracellular levels of DA and NE within the PFC, nucleus
accumbens (NAcc), and medial septal area (MSA). Data are an average (±SEM) of three 30min samples following MPH application and are expressed as percent above baseline. At
this concentration, MPH produced only modest increases in DA and NE levels (~50–60%)
in subcortical regions (NAcc and MSA), while eliciting significantly larger increases in DA
and NE levels (~100–120%) within the PFC. A similar pattern of effects is seen with
systemic administration of clinically-relevant doses of MPH (see Figure 2). *P<0.05 relative
to NAcc DA and +P<0.05 relative to MSA NE. From 43.
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Fig 4. Similar neurochemical actions in the prefrontal cortex (PFC) of a selective norepinephrine
reuptake inhibitor (SNRI) and a selective dopamine reuptake inhibitor (SDRI)

Shown are the mean (±SEM) change in extracellular norepinephrine (NE) in the PFC and
extracellular dopamine (DA) in the PFC and nucleus accumbens (NAcc) expressed as a
percent change from baseline. Data are shown for 30-min samples collected prior to
(negative numbers) and following (positive numbers) systemic treatment with either (A) the
selective NE inhibitor (SNRI), atomoxetine (3 mg/kg) or (B) the selective DA inhibitor
(SDRI), AHN 2005 (10 m/kg). At these doses, these drugs exert cognition-enhancing
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effects. A: The SNRI elicited similar increases in extracellular levels of both NE and DA
(~150% above baseline) while having no effect on DA within the NAcc. B: The SDRI also
elicited significant increases in both extracellular DA and NE in the PFC that were
comparable in magnitude (~100% above baseline). However, in contrast to the SNRI, the
SDRI elicited a relatively large increase in extracellular DA levels in the NAcc (~200%
above baseline). Panel A adapted from 49. Panel B adapted from 53. Error bars removed for
clarity. *P< 0.05, compared to vehicle-treated animals.
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Fig 5. Cognition-enhancing effects of methylphenidate (MPH) involve actions within the
prefrontal cortex (PFC)
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Shown are the effects of intra-PFC infusion of MPH on performance in a test of working
memory expressed as percent change from baseline (mean ± SEM). Top Panels: Infusion of
methylphenidate into the dmPFC (A) but not vmPFC (B) improved working memory in an
inverted-U dose-dependent manner, with 0.125 µg/hemisphere producing maximal
improvement. The magnitude of MPH-induced improvement in performance was
comparable to that seen with systemic administration of clinically relevant doses (see Figure
1). Note that doses 4 and 16-fold higher than an optimal dose infused into the dmPFC do not
impair performance as seen with systemic administration. Bottom Panels: Schematic
diagram indicating all 0.125 µg infusion sites into the dmPFC (A) and vmPFC (B). Numbers
represent anterior-posterior (AP) level (data from [Swanson]). *P<0.05 relative to vehicle
treatment. dAcg, dorsal anterior cingulate; IL, infralimbic; PL, prelimbic.
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Fig 6. Different PFC-dependent cognitive tasks show differential sensitivity to methylphenidate

Methylphenidate (MPH) exerts a relatively narrow inverted-U shaped facilitation of working
memory performance (A), with maximal improvement seen following 0.5 mg/kg I.P. In
contrast, MPH exerts a right shifted dose-dependent facilitation of sustained attention (A)
and attentional set shifting (B). Importantly, doses that improve sustained attention and
attentional set shifting impair performance in working memory (2.0 mg/kg). **P <0.01
compared to vehicle treatment. Data from (98).

Biol Psychiatry. Author manuscript; available in PMC 2016 June 01.

